Arcturus Therapeutics (ARCT) is scheduled to report 2nd quarter earnings on 08/07/2023, after the market closes.
Regarding Q2 estimates, Wall Street analysts expect Arcturus Therapeutics to post earnings of -$0.25 per share. Revenue expectations are pegged at $49.33 million. Last quarter, Arcturus Therapeutics beat earnings estimates, reporting EPS of $1.87 on estimates of $0.06. The stock rose by 1.59% the day after the last earnings release.
Year-to-date, ARCT stock has risen by 92.51%.
Is Arcturus Therapeutics Stock a Buy?
Wall Street’s consensus rating for ARCT stock is a Moderate Buy, with an average analyst price target of $58.40, implying upside potential of 81.65% from current levels.
ARCT shares have gained about 46.34% in the past six months.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
